

Flu Resource Order Form

Please photocopy and use this form as many times as you need

Practice Name:	Contact Name:	
Address:	Phone:	Date:
	Email:	

FLU FIT		PRINT NUMBER REQUIRED	DIGITAL VERSION REQUIRED	FLUAD Quad		PRINT NUMBER REQUIRED	DIGITAL VERSION REQUIRED
	Flu Brochure				65+ FLUAD® Quad Poster (Double sided)		
	Flu 'get immunised' poster (2 kinds)				FLUAD Quad Brochure holder		
	Flu information poster				FLUAD Quad Brochure		
	'I've been immunised' Stickers (Available in Sheets and Rolls)				FLUAD Quad A5 information handout		
	'I've been immunised' Stickers - Te Reo version (Available in Sheets)						
	Get immunised Flu badges						

Scan and email this form to customer.service.nz@seqirus.com

FLUAD® Quad is an unfunded Prescription Medicine. FLUAD® Quad is an inactivated influenza vaccine, with an MF59® Adjuvant, as a suspension for injection in a single-dose prefilled glass syringe. **PRESENTATION:** Each 0.5 mL dose contains 15 mcg of surface haemagglutinin from four influenza virus strains. **INDICATIONS:** For active immunisation against influenza, for people 65 years of age and older. **CONTRAINDICATIONS:** Severe allergic reaction (e.g. anaphylaxis) to a previous influenza vaccination or to the active substances, adjuvant, or any other constituents or trace residues. Persons with a history of egg allergy (non-anaphylaxis) can receive a full dose of vaccine in any immunisation setting. **ADVERSE EVENTS: Common** injection site pain, fatigue and headache. Most of these reactions disappear within 3 days. **Rare** but serious events include thrombocytopenia; lymphadenopathy; muscular weakness; allergic reactions such as anaphylactic shock, anaphylaxis; encephalomyelitis, Guillain Barré syndrome, neuritis, neuralgia, paraesthesia, or convulsions; vasculitis with transient renal involvement; generalised skin reactions; and severe injection-site reactions (extensive limb swelling or cellulitis-like reactions). **PRECAUTIONS:** Postpone immunisation in patients with acute febrile illness or infection. Antibody responses may not be protective in all vaccinees, particularly in immunosuppressed patients. FLUAD® Quad is not for intravascular or subcutaneous administration. Persons with a history of anaphylaxis to egg should be vaccinated only in medical facilities with staff experienced in recognising and treating anaphylaxis. Co-administration with other vaccines has not been studied. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give FLUAD® Quad should be based on careful consideration of the potential benefits and risks. **DOSAGE AND ADMINISTRATION:** Gently shake before use to produce a milky-white suspension; inject a single 0.5 mL dose into the deltoid muscle. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the FLUAD® Quad Data Sheet at www.medsafe.govt.nz, or from Seqirus (NZ) Ltd, Auckland. FLUAD® and FLUAD® Quad are registered trademarks of Seqirus UK Ltd. 10/21. NZL-FLU-22-0029. TAPS DA2206ER. INSIGHT 12251.